The Case for Starting Hormone Therapy Before Menopause
Conventional medical guidance historically directed women to wait until menopause — the cessation of menstrual periods for 12 consecutive months — before initiating hormone therapy. This approach left millions of women suffering through years of perimenopausal symptoms without treatment, and may have missed the optimal window for preventive benefits regarding bone, cardiovascular, and cognitive health.
Current evidence and evolving clinical practice strongly support initiating hormone therapy during perimenopause — when symptoms are already present, when ovarian function is declining but not yet ceased, and when the preventive window for long-term health benefits is widest.
What Is Perimenopause?
Perimenopause is the transition from full reproductive function to menopause. It typically begins in the early-to-mid 40s (occasionally late 30s) and is characterized by irregular, erratic fluctuations in estrogen and progesterone. It ends with the final menstrual period and is followed by the postmenopausal state.
During perimenopause, estrogen does not simply decline smoothly — it fluctuates chaotically, sometimes surging well above premenopausal levels before crashing. This volatility, combined with progressive progesterone deficiency, produces the majority of perimenopausal symptoms. Many women experience more intense symptoms during late perimenopause than after menopause, precisely because of this erratic fluctuation.
Why Early Treatment Matters
The “timing hypothesis” in hormone therapy — supported by multiple major trials — holds that the cardiovascular, bone, and neuroprotective benefits of HRT are substantially greater when therapy is initiated within 10 years of menopause or before age 60. This window reflects the relative absence of pre-existing subclinical vascular disease and the preserved responsiveness of estrogen receptor systems in younger postmenopausal and perimenopausal women.
Starting during perimenopause — before menopause — positions women to receive continuous hormone support through the transition, preventing the years of untreated deficiency that accelerate bone loss, vascular inflammation, and neurological aging. Bone density that is lost during perimenopause cannot be fully recovered; brain volume changes associated with estrogen withdrawal in the early menopausal transition may have lasting effects on cognitive reserve.
Managing the Erratic Hormones of Perimenopause
Treating perimenopause with hormone therapy is more nuanced than postmenopausal HRT, because the ovaries are still producing variable amounts of hormones — meaning standard postmenopausal dosing may be inadequate in some cycles and redundant in others. The most evidence-based approach for symptomatic perimenopausal women with regular or irregular cycles is:
- Low-dose transdermal estradiol (to stabilize the erratic baseline) — often sufficient to eliminate hot flashes, improve sleep, and stabilize mood without suppressing residual ovarian function
- Cyclic micronized progesterone (days 12–26 of cycle, if still cycling) — to oppose estrogen’s endometrial effects and provide the luteal-phase progesterone that declining ovarian function no longer reliably provides
- Adjustment as cycles become more irregular and eventually cease
How to Get Started at Multigen Wellness
A perimenopausal hormone evaluation at Multigen Wellness begins with a comprehensive hormone panel and detailed symptom assessment. Cycle status, symptom pattern, and lab values guide an individualized protocol that is refined over time as the transition progresses. Telehealth consultations are available same-week in TX, AZ, MI, NY, UT, and FL.
You do not have to wait for your last period to get relief from hormone symptoms. Call Multigen Wellness at (800) 259-0015 to start your evaluation today.